BACKGROUND AND AIMS: With the change in antidiabetic medications, the trend of glycaemic management is still unclear for type 2 diabetes mellitus (T2DM) patients, especially those with cirrhosis. We aimed to examine secular trends in glycaemic control and antidiabetic medication usage among T2DM patients with or without cirrhosis. METHODS: ) < 7% and fasting blood glucose < 7.2 mmol/L, as well as the trend of antidiabetic medication usage and hypoglycaemia incidence, were examined. RESULTS: target over the years, with compensated cirrhosis group having the best control (from 2000-04 to 2020-23: non-cirrhosis group: 39.2% to 65.9%, compensated cirrhosis group: 49.3% to 75.8%, decompensated cirrhosis group: 47.6% to 64.6%). The probability of achieving glycaemic targets increased over time in all groups. Insulin was the predominant agent in decompensated cirrhosis group, with an increasing incidence of hypoglycaemia. CONCLUSION: Glycaemic control improved in T2DM patients irrespective of cirrhosis status. Further research is needed to determine the impact of sustained control on hepatic and extrahepatic outcomes.
Wang et al. (Tue,) studied this question.